Jubilant HollisterStier Announces New President & Upcoming Availability of Expanded Production Capacity for Sterile Injectables
Jubilant HollisterStier (JHS) recently announced the appointment of Chris Preti as President. He brings more than 25 years of broad pharmaceutical industry experience to JHS.
Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President. Chris holds a Bachelor of Science degree and Master of Science degree in Chemistry from Furman University and a Master of International Business Studies degree from the Darla Moore School of Business at the University of South Carolina. Chris also completed the program in Transformational Leadership for Executives at the Wharton School of the University of Pennsylvania.
As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~$285 million to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well. The investment is part of the company’s cooperative agreement providing $149.6 million from the US Government to expand its critical vaccine manufacturing capacity in the US.
Chris Preti commented “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide. As a leading contract manufacturer of injectable pharmaceutical products and sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, we are acutely aware of the supply chain issues that continue to challenge manufacturers. With this expansion, we are well-positioned to address the contract manufacturing needs of major producers throughout North America. My decades in the Pharma industry taught me the critical role of manufacturing in achieving commercial success, and I am delighted to be heading up an industry leader committed to providing the highest quality comprehensive services in partnership with our customers.”
Jubilant HollisterStier, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full range of support to streamline manufacturing, from process qualifications through commercial release. For more information, visit www.jublhs.com.
Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated markets, including the US, Europe, and other geographies. The Company has a team of around 3,500 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a Partner of Choice by leading pharmaceutical companies globally. For more information, visit www.jubilantpharma.com.
Total Page Views: 1267